Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 6
Opinion
Video
Other Emerging Intravesical Therapies in NMIBC
Author(s):
Panelists discuss how both TAR-200 and UGN-102/103 represent innovative approaches to intravesical drug delivery for bladder conditions. TAR-200 uses a novel silicone-based system designed for controlled gemcitabine release, potentially offering extended drug exposure compared with conventional instillations. UGN-102 and UGN-103 employ a proprietary RTGel technology that transforms from liquid to gel form at body temperature, allowing for longer retention of mitomycin (UGN-102) and high-dose botulinum toxin (UGN-103), respectively, in the bladder.
Video content above is prompted by the following:
- What are your thoughts on novel continual intravesical release technologies that are currently in clinical trials?
- TAR-200 (SunRISe trials)
- UGN-102 (ENVISION) and UGN-103 (UTOPIA)
Related Videos
Related Content
